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IL-1β plays a crucial role in the differentiation of human Th17 cells. We report here that 
IL-1RI expression is significantly increased in both naive and memory CD4+ T cells 
derived from relapsing-remitting multiple sclerosis (RR MS) patients in comparison to 
healthy controls. Interleukin 1 receptor (IL-1R)I expression is upregulated in the in vitro- 
differentiated Th17 cells from RR MS patients in comparison to the Th1 and Th2 cell sub-
sets, indicating the role of IL-1R signaling in the Th17 cell differentiation in RR MS. When 
IL-1RI gene expression was silenced using siRNA, human naive CD4+ T cells cultured 
in the presence of Th17-polarizing cytokines had a significantly decreased expression 
of interleukin regulatory factor 4 (IRF4), RORc, IL-17A, IL-17F, IL-21, IL-22, and IL-23R 
genes, confirming that IL-1RI signaling induces Th17 cell differentiation. Since IL-1R gene 
expression silencing inhibited IRF4 expression and Th17 differentiation, and IRF4 gene 
expression silencing inhibited Th17 cell differentiation, our results indicate that IL-1RI 
induces human Th17 cell differentiation in an IRF4-dependant manner. Our study has 
identified that IL-1RI-mediated signaling pathway is constitutively activated, leading to 
an increased Th17 cell differentiation in IRF4-dependent manner in patients with RR MS.
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inTrODUcTiOn
IL-1β induces differentiation of T helper (Th) 17 cells, which play a critical role in the develop-
ment of the autoimmune response. IL-1β contributes to IL-6-induced RORc expression and IL-17A 
production in humans (1, 2), consistent with animal studies in which IL-1β has a synergistic effect 
with IL-23 in promoting Th17 differentiation (3, 4). The role of IL-17 in MS and other autoim-
mune disorders has been demonstrated in multiple studies. IL-17 mRNA and protein expression is 
Abbreviations: EAE, experimental autoimmune encephalomyelitis; HCs, healthy controls; IL-1R, interleukin-1 receptor; IRF, 
interferon regulatory factor; PBMCs, peripheral blood mononuclear cells; RR MS, relapsing-remitting multiple sclerosis; SNs, 
supernatants, TCR, T cell receptor.
2Sha and Markovic-Plese Activated IL-1RI Signaling Induces Th17 Differentiation in RR MS
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 543
elevated in the active MS brain lesions (5, 6), where it is present 
in both CD4+ and CD8+ T cells, as well as in astrocytes and 
oligodendrocytes. IL-17 gene expression is significantly higher 
in mononuclear cells derived from the blood and cerebrospinal 
fluid (CSF) of MS patients when compared to healthy controls 
(HCs), and the numbers of IL-17-expressing blood mononuclear 
cells are higher during MS exacerbations in comparison to clini-
cally silent periods (7). IL-17 has also been detected in the target 
organs of other autoimmune diseases, including rheumatoid 
arthritis, psoriasis, and autoimmune uveitis (8), suggesting its 
role in human autoimmune responses.
Upon binding of IL-1 to IL-1RI, an interleukin-1 receptor 
(IL-1R) accessory protein (AcP) is recruited to form a high 
affinity IL-1RI-IL-1RAcP heterodimeric receptor, which initi-
ates the recruitment of the MyD88 adapter and its activation 
and association with IRAK4. Tumor necrosis factor (TNF) 
receptor-associated factor (TRAF) 6 is subsequently recruited to 
the receptor-associated IRAK1–IRAK4–MyD88 adaptor protein 
complex. The formation of this complex leads to the induction 
of the MAPK p38 cascade and the activation of NF-κB signaling 
pathway (9–11). These signaling pathways lead to the expression 
of a range of cytokines involved in inflammatory responses.
Interleukin-1 receptor signaling in T cells is required for the 
early programing of Th17 cell differentiation and Th17 cell-
mediated autoimmunity (12). Th17 cells, which are characterized 
by the production of IL-17, are considered a key player in the 
pathogenesis of autoimmune diseases (6, 13). Naive CD4+ T 
cells require IL-1β plus IL-23, IL-6, and TGFβ to differentiate 
into Th17 cells (1, 14–17). Transcription factors STAT3, RORα 
and RORγτ determine Th17 cell lineage-specific differentiation 
program through induction of a set of signature cytokines and 
cytokine receptors, including IL-1R (18, 19). IL-1R1 expression 
in T cells is necessary for the Th17 cell differentiation (12, 20). 
Mice defective in IL-1RI signaling were resistant to experimental 
allergic encephalomyelitis (EAE) and exhibit a defect in the 
generation of IL-17-producing T cells, suggesting that IL-1RI 
signaling in T cells is required for Th17 cell differentiation (21, 
22). Single immunoglobulin IL-1-related receptor (SIGIRR), 
a negative regulator of IL-1R signaling, was induced during 
Th17 cell commitment and suppressed Th17 cell proliferation 
through its inhibitory effects on IL-1R signaling (22). In human 
peripheral blood, CD4+ T cells that express IL-1RI have the 
capacity to produce IL-17 in naive and memory T cells. IL-R1+ 
memory cells had increased gene expression of IL-17, RORc, and 
interleukin regulatory factor 4 (IRF4), even before T cell receptor 
(TCR) triggering, suggesting that IL-1R1 expression renders cells 
committed to Th17 differentiation (20). IL-1RI+ naive CD4+ T 
cells produce higher levels of IL-17 in response to a combination 
of IL-1β and TCR triggering compared to IL-1RI− naive CD4+ 
T cells, which are capable of producing IL-17 only upon TCR 
stimulation-induced IL-1R1 expression (20).
Previous studies have shown that the human Th17-polarizing 
cytokines are different from those in mice. In mice, IL-6 plays 
a critical role and IL-1β exerts an enhancing effect, whereas 
in humans, IL-1β is essential and IL-6 enhances its effect on 
Th17 cell differentiation. It has been reported that, in healthy 
individuals, IL-1β alone induces RORc and IL-17 expression, 
which is sustained in the presence of IL-6. Moreover, in cultures 
stimulated with IL-1β or IL-1β plus IL-6, the addition of IL-23 
increases the percentage of IL-17-producing T cells in long-term 
cultures, which is more prominent in cultures stimulated with 
IL-1β alone (20).
The goal of this study was to characterize the role of IL-1R1 
signaling in promoting human Th17 cell differentiation in the 
context of their role in the development of the autoimmune 
response in patients with relapsing-remitting multiple sclerosis 
(RR MS). Our results may provide rationale for therapeutic 
targeting of IL-1RI in autoimmune diseases.
MaTerials anD MeThODs
study subjects
Thirty-two patients with confirmed diagnoses of RR MS and 35 
HCs were enrolled in the study upon signing an institutional 
review board (IRB)-approved informed consent. The study was 
approved by the University of North Carolina IRB. The inclusion 
criteria for the MS patients consisted of a confirmed diagnosis of 
RR MS according to McDonald’s diagnostic criteria, age 18–55, 
and an extended disability status score (EDSS) 1.5–5.5. The 
patients were not treated with immunomodulatory therapy at the 
time of blood collection. The treatment-free period was at least 
6 weeks for IV methylprednisolone, 3 months for interferon-beta 
and glatiramer acetate, and 6 months for tecfidera, teriflunomide, 
and fingolimod.
cell cultures
CD4+, CD4+CD45RA+, and CD4+CD45RO+ T cells were iso-
lated from peripheral blood mononuclear cells (PBMCs) using 
magnetic beads (Miltenyi Biotech). Cell purity was confirmed by 
flow cytometry (>95%). Cells were maintained after separation 
in RPMI 1640 complete medium supplemented with 10% fetal 
bovine serum (FBS), 2 mM glutamine, and 100 U/ml penicillin G 
and streptomycin. For the ex vivo gene expression measurements, 
CD4+, CD4+CD45RA+, and CD4+CD45RO+ T cells were cultured 
at 2 × 106 cells/ml in serum-free medium (Opti-MEM I, Gibco) for 
6 h prior to RNA extraction. In order to generate different T cell 
subsets, CD4+CD45RA+ naive T cells were stimulated with plate-
immobilized anti-CD3 (1 μg/ml) and anti-CD28 (5 μg/ml) mAb 
and cultured in serum-free medium in the absence or presence of 
(a) Th1-polarizing cytokines IL-12 (10 ng/ml), IFN-γ (3 ng/ml), 
and anti-IL-4 mAb (10 ng/ml); (b) Th2-polarizing cytokines IL-4 
and anti-IL-12 mAb (10 μg/ml); or (c) Th17-polarizing cytokines 
IL-1β, IL-6, IL-23 (all at 50 ng/ml), TGFβ (10 ng/ml), anti-IL-4 
mAb, anti-IL-27 mAb, and anti-IFNγ mAb (all at 10 μg/ml). After 
72 h, the cells were harvested for gene expression RT-PCR studies. 
In the Th17 cell differentiation experiments following IL-11R and 
IRF4 siRNA, the cells were harvested at 72 h for RNA extraction, 
and the supernatants (SNs) were collected from the same cell 
cultures for cytokine measurement by ELISA.
Quantitative rT-Pcr
Total RNA was isolated from CD4+, CD4+CD45RA+, 
CD4+CD45RO+ T cells and reverse-transcribed to cDNA using 
an iSCRIPT cDNA synthesis kit (Bio-Rad). Quantitative RT-PCR 
FigUre 1 | il-1ri gene expression is increased in cD4+, cD4+cD45ra+, and cD4+cD45rO+ cells from rr Ms patients in comparison to hcs. CD4+, 
CD4+CD45RA+ naive, and CD4+CD45RO+ memory T cells derived from six RR MS patients and six HCs were separated using magnetic beads. The total RNA was 
harvested and the gene expression of IL-1RI and 18S was measured using qRT-PCR. The results are presented as the relative gene expression normalized against 
18S mRNA. Statistical analysis was performed using unpaired t-test.
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(qRT-PCR) was performed using an Applied Biosystems PRISM 
7700 Sequence System. The primers were purchased from 
Applied Biosystems. Each sample was analyzed in triplicate. 
Relative gene expression was expressed upon normalization 
against 18S RNA.
sirna experiment
The siRNAs for IL-1R1, IRF4, and control A siRNA were pur-
chased from Santa Cruz Biotechnology. 2 × 106 CD4+CD45RA+ 
cells per condition were transfected with each of the listed 
siRNAs using human T cell Nucleofector kit (Lonza). They 
were then stimulated with plate-immobilized anti-CD3 (1 μg/
ml) and anti-CD28 (5 μg/ml) mAb and cultured in serum-free 
medium (Opti-MEM I, Gibco) in the absence or presence of 
Th17-polarizing cytokines. After 72 h, the cells were harvested 
for gene expression studies and their cytokine production was 
measured in SNs.
Western Blotting
CD4+CD45RA+ cells were plated at 2 × 106 cells per condition for 
Western blotting. The cells were lysed with lysis buffer containing 
2.5  mM sodium pyrophosphate, 1  mM NA3VO4, and 1  mM 
phenylmethylsulfonyl fluoride (Santa Cruz Biotechnology). 
The cell lysates were resolved with 5–15% gradient SDS-PAGE 
(Bio-Rad) and transferred to polyvinylidene difluoride (PVDF) 
membranes. The membranes were blocked with 5% milk in 
TBS (20  mM Tris and 500  mM NaCl) and 0.1% Tween 20 at 
room temperature for 1  h followed by overnight incubation at 
4°C with primary Abs against IL-1RI (Abcam), IRF4 (Santa 
Cruz Biotechnology), RORc (Abcam), β-actin (Sigma-Aldrich). 
Secondary HRP-conjugated Ab (Santa Cruz Biotechnology) was 
added at a dilution of 1/2000 for 1  h and the protein bands 
were detected with an ECL Detection System (Santa Cruz 
Biotechnology).
elisa
Supernatants from the cell cultures were collected and stored at 
−80°C until the cytokine measurements. IL-17A, IL-17F, IL-21, 
IL-22 (all from eBiosciences), IL-4, and IFN-γ (both from BD 
Pharmingen) were measured in duplicate by ELISA following the 
manufacturer’s recommendation. Results are expressed for each 
subject as cytokine concentration in pictogram per milliliter.
statistics
Statistical analyses of the ex vivo qRT-PCR results were performed 
using a t-test analysis (GraphPad, InStat). Statistical analyses of 
the comparisons for multiple groups were performed using a 
repeated measure ANOVA (GraphPad, InStat). p Values <0.05 
were considered significant.
resUlTs
il-ri gene expression is significantly 
increased in Both naive and Memory cD4+ 
cells Derived from rr Ms Patients in 
comparison to hcs
Our previously published gene expression profiling study of the 
ex vivo separated PBMCs from patients with clinically isolated 
syndrome (CIS) suggestive of MS has reported that IL-1R is the 
most significantly upregulated gene in comparison to HCs (23).
In this study, we found an increased IL-1RI gene expression in 
CD4+, CD4+CD45RA+, and CD4+CD45RO+ cells derived from 
RR MS patients in comparison to HCs (Figure 1). The expression 
of IL-1RI on memory CD4+ cells is significantly higher than on 
the naive cells in both RR MS patient and HCs (Figure 1), consist-
ent with the results in healthy individuals reported by Lee et al. 
(20). While those authors have studied the IL-1RI+ cells, which 
represent 20% of CD4+ cells in healthy donors, and identified that 
FigUre 2 | il-1r1 expression is higher in the in vitro-differentiated 
Th17 cells in comparison to Th1 and Th2 cultures. CD4+CD45RA+ 
cells were derived from three HCs and stimulated with plate-immobilized 
anti-CD3 and anti-CD28 mAb in a serum-free medium in the absence or 
presence of Th1, Th2, or Th17-polarizing cytokines. After 72 h, total RNA 
was extracted and gene expression of IL-1R1 and 18S was measured by 
RT-PCR. The results are expressed as relative gene expression normalized 
for 18S mRNA expression. Statistical analysis was performed using ANOVA. 
***p < 0.001.
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the frequency of naive CD4+ cells is lower, while the frequency of 
memory CD4+ cells is higher in IL-1RI+ than in IL-1RI− cells, our 
results provide further insight into the differential gene expres-
sion of IL-1RI in both CD4+ cell subsets in RR MS patients in 
comparison to HCs.
In Vitro-Differentiated Th17 cells express 
significantly higher levels of il-1ri in 
comparison to Th1 and Th2 cells
IL-1RI gene expression was detected in naive CD4+CD45RA+ 
cells differentiated in the presence of Th1 (IL-12, IFN-γ, and 
anti-IL-4 mAb), Th2 (IL-4 and anti-IL-12 mAb), or Th-17 (IL-1β, 
IL-6, IL-23, TGF-β, anti-IL-4 mAb, anti-IL-27, and anti-IFN-γ 
mAb)-polarizing cytokines. We have identified that the in vitro-
differentiated Th17 cells express significantly higher levels of 
IL-RI in comparison to the Th1 and Th2 cells (Figure 2). Our 
results are consistent with a previous study on the increased 
expression of IL1-RI in in vitro-differentiated Th17 mouse cells 
(12), as well as with our previously published study reporting 
higher IL-1R protein expression in IL-17A+CD4+ (Th17) cells 
in comparison to IFN-γ+CD4+ (Th1) and IL-4+CD4+ (Th2) cells 
from CIS patients (23).
il-1ri activation induces human Th17 
cell Differentiation
In order to directly demonstrate the effect of IL-1RI signaling 
on the Th17 cell differentiation, control siRNA A, and siRNA 
IL-1RI-transfected naive CD4+ cells derived from HCs and 
RR MS patients were cultured in the absence or presence 
of Th17-polarizing cytokines. In the CD4+CD45RA+ cells 
derived from HCs, the Th17-polarizing cytokines induced 
a significantly higher expression of IL-1R1, IRF4, RORc, 
IL-17A, IL-17F, IL-21, IL-22, and IL-23R Th17 cell markers in 
comparison to baseline. In contrast, siRNA IL-1RI-transfected 
cells derived from HCs exhibited a decreased expression 
of those Th17-related genes upon Th17 differentiation 
(Figure  3A). In CD4+CD45RA+ cells derived from RR MS 
patients (Figure 3B), gene expressions of IL-1RI, IRF4, RORc, 
IL-17A, IL-17F, IL-21, and IL-23R were even more increased 
upon stimulation with Th17-polarizing cytokines than in HCs. 
The induction of IL-1RI, IRF4, RORc, IL-17A, IL-17F, IL-21, 
and IL-23R were inhibited in the siRNA IL-1RI-transfected 
cells. The studies of the naive CD4 cells with silenced IL-1RI 
expression confirmed that IL-1RI signaling is essential for 
human Th17 cell differentiation. Our results demonstrated 
preferential Th17 cell differentiation in RR MS patients in 
comparison to HCs, since the gene expression of IL-1R1, IRF4, 
RORc, IL-17A, IL-17F, IL-21, IL-22, and IL-23R were higher 
in MS patients than in HCs at baseline and following Th17 
cell differentiation (Figures  3A,B).
il-1ri signaling is required for the 
secretion of Th17 cytokines
The subsequent studies have examined to what extent have IL-1RI-
mediated signaling modified naive CD4+ cell cytokine secretion 
following Th17 cell differentiation. We measured cytokine 
concentrations in the SNs of the naive CD4+ cells with silenced 
IL-1RI expression in the absence or presence of Th17-polarizing 
cytokines using ELISA. The results revealed that IL-17A, IL-17F, 
IL-21, and IL-22 secretion induced in naive CD4+ cells derived 
from the HCs in the presence of Th17-polarizing cytokines were 
significantly suppressed upon silencing of their IL-1RI expres-
sion (Figure 4A). In the naive CD4+ cells derived from RR MS 
patients, IL-17A, IL-17F, and IL-21 secretion induced in the pres-
ence of Th17-polarizing cytokines was significantly suppressed 
by siRNA IL-1RI (Figure 4B). IL-17A, IL-17F, IL-21, and IL-22 
are significantly induced in MS patients compared to HCs at 
baseline, and upon stimulation with Th17-polarizing cytokines 
(Figures 4A,B), confirming preferential IL-1R-induced Th17 cell 
differentiation in RR MS.
il-1ri induction of Th17 cell 
Differentiation is irF4-Dependent
Interleukin regulatory factor 4 gene expression in CD4+ T 
cells derived from RR MS patients was significantly increased 
in comparison to those from HCs (Figure 5A). Western blot-
ting studies of the naive CD4+CD45RA+ cells transfected with 
siRNA IL-1RI demonstrated a significant inhibition of IL-1RI 
protein expression (85% suppression), which was associated 
with a decreased expression of IRF4 and RORc in both HCs 
and RR MS patients (Figure  5B). These results indicate that 
IL-1RI signaling induces IRF4 and RORc expression in human 
naive CD4+ cells. In order to directly examine the role of IL-1RI 
and IRF4 signaling in human Th17 cell differentiation, the IRF4 
gene expression was silenced using a siRNA approach. The 
FigUre 3 | il-1r1 signaling induces Th17 cell differentiation. CD4+CD45RA+ cells were derived from three HCs (a) and seven RR MS patients (B) and 
transfected with a control siRNA A or siRNA IL-1R1, stimulated with plate-immobilized anti-CD3 and anti-CD28 mAb and cultured in serum-free medium in the 
absence or presence of Th17-polarizing cytokines. The total RNA was extracted at 72 h, and the expression of the indicated genes was measured using RT-PCR. 
The results are expressed as relative gene expression normalized against 18S mRNA expression. Statistical analysis was performed using repeated measures 
ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001.
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FigUre 5 | il-1r1 and irF4 are required for human Th17 cell 
differentiation. (a) IRF4 gene expression in the CD4+ T cell from RR MS 
patients is significantly increased in comparison to HCs. CD4+ T cells derived 
from six RR MS patients and six HCs were separated using magnetic beads, 
and the total RNA was extracted. The gene expression of IRF4 and 18S was 
measured by RT-PCR. The results are expressed as relative gene expression 
normalized for 18S mRNA expression. Statistical analysis was performed 
using t-tests. *p < 0.05. (B) IL-1R1 gene silencing downregulates IRF4 and 
RORc protein expression in CD4+CD45RA+ cells from RR MS patients and 
inhibits Th17 cell differentiation.
FigUre 4 | il-1r1 signaling induces secretion of Th17 cytokines. 
CD4+CD45RA+ cells were derived from three HCs (a) and three RR MS 
patients (B), transfected with a control siRNA A or siRNA IL-1R1, stimulated 
with plate-immobilized anti-CD3 and anti-CD28 mAb and cultured in 
serum-free medium in the absence or presence of Th17-polarizing cytokines. 
After 72 h, the supernatants were collected and the cytokine production 
measured by ELISA. Statistical analysis was performed using a repeated 
measures ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001.
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naive CD4+CD45RA+ cells from RR MS patients, which were 
transfected with siRNA IRF4, exhibited significant inhibition of 
the induction of IL-1RI, IRF4, RORc, IL-17A, IL-17F, IL-21, and 
IL-23R gene expression (Figure 6).
DiscUssiOn
This study has demonstrated that IL-1RI expression is sig-
nificantly higher in both the naive and memory CD4+ T cells 
derived from RR MS patients in comparison to those from HCs. 
In vitro-differentiated Th17 cells express higher levels of IL-RI 
than Th1- or Th2-differentiated cells. Finally, the siRNA silenc-
ing of IL-1RI in naive CD4+ cells inhibited in  vitro Th17 cell 
differentiation, by inhibiting IRF4 and RORc, as well as IL-17A, 
IL-17F, IL-21, IL-22, and IL-23R gene expression. Cytokine secre-
tion measurements detected a significantly decreased IL-17A, 
IL-17F, and IL-21 secretion by the siRNA IL-1R1-transfected 
naive in vitro polarized Th17 cells, indicating that IL-1R1 signal-
ing induces Th17 cell differentiation. Our study has identified 
that increased IL-1R1 expression in multiple CD4+ cell subsets 
may reflect this pathway’s activation in patients with RR MS, 
leading to an increased Th17 cell expansion and autoimmune 
response.
Interleukin regulatory factor 4 is a transcription factor that 
serves as a key regulator of both Th2 and Th17 differentiation 
(24, 25). Our previously published results identified IRF4 as a 
key transcription factor for the human Th17 cell differentiation 
using both IRF4 gene expression silencing and overexpression 
(26). IRF4 induces Th2 differentiation via upregulation of the 
Th2 transcription factor GATA-3 and interaction with the tran-
scription factor NFAT (27–29). IRF4-deficient T helper cells had 
less expression of RORγt and more expression of Foxp3 and did 
not differentiate to Th17 cells. IRF4-deficient mice are protected 
from EAE (24). The transcription factor RORγt plays a crucial 
role in the development of Th17 cells (30). IRF4 deficiency is 
associated with a decrease in IL-6-induced RORγt expression 
that impedes Th17 differentiation (24). The published obser-
vations have shown that IRF4 controls experimental colitis 
in mice via T cell-derived IL-6 (31), and that IL-6 suppresses 
FigUre 6 | il-1r1 positively regulates human Th17 cell differentiation in an irF4-dependent manner. CD4+CD45RA+ cells from six RR MS patients 
transfected with a control siRNA A or siRNA IRF4 were stimulated with plate-immobilized anti-CD3 and anti-CD28 mAb and cultured in serum-free medium in the 
absence or presence of Th17-polarizing cytokines. After 72 h, the total RNA was extracted. The gene expression was measured by RT-PCR. The results are 
expressed as relative gene expression normalized for 18S mRNA expression. Statistical analysis was performed using ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001.
7
Sha and Markovic-Plese Activated IL-1RI Signaling Induces Th17 Differentiation in RR MS
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 543
TGFβ-induced development of regulatory T cells and Foxp3 
expression (4, 32). In normal Th17 cells, IL-6-mediated down-
regulation of Foxp3 is needed to counteract the upregulation 
of Foxp3 by TGFβ (33). IRF4 can interact with NFATc1 and 
NFATc2 in T helper cells (27, 29) and with the transcription 
factors PU.1 and STAT6 in B cells (34, 35). In addition, IRF4-
binding protein (IBP) inhibits IL-17 and IL-21 production by 
controlling IRF4 function, which directly binds to the IL-17 and 
IL-21 promoters and induces their transcriptional activation 
(36). More recently, it has been reported that IRF4 is also crucial 
for the development and function of an IL-9-producing CD4+ 
T cell subset designated Th9. The study has reported that IL-9 
production in human CD4+ T cells is induced by the upregula-
tion of IRF4 (37).
IL-1RI signaling is a critical step in human Th17 cell dif-
ferentiation, leading to the induction of IRF4 and RORc. In our 
study, the expressions of IL-1RI, IRF4, and RORc increased upon 
stimulation with Th17-polarizing cytokines in CD4+CD45RA+ 
cells derived from RR MS patients and HCs, indicating that 
IRF4 and RORc are Th17 cell lineage transcription factors. 
IL-1RI gene silencing by siRNA in naive CD4+CD45RA+ cells 
leads to a significant inhibition of IL-1RI protein expression, as 
well as IRF4 and RORc, in both HCs and RR MS patients in a 
Th17-polarizing condition. When we knocked down the IRF4 
gene expression in naive CD4+ cells using siRNA IRF4, Th17-
polarizing condition failed to induce Th17 cell differentiation 
and the expression of RORc was inhibited, indicating that RORc 
signals downstream of IRF4. Activated IL-1RI induces IRF4 
expression, which causes the activation and induction of RORc 
and IL-17. Our results indicate that IL-1RI signaling may induce 
IRF4 and RORc protein expression during human Th17 cell 
differentiation, consistent with the results by Chung et al. who 
reported that IL-1RI-deficient mouse T cells failed to express 
IRF4 and RORc (12).
The IL-1R1 signaling pathway has received a renewed atten-
tion due to its recently reported induction of transcription factor 
Bhlhe40 associated with Th17 cell encephalitogenic phenotype 
and GM-CSF secretion (38). Furthermore, the role of IL-1 signal-
ing in the generation of autoimmune responses was most recently 
documented by the production of IL-1 by neutrophils and mono-
cytes as they migrate to the CNS and induce IL-1R signaling in 
endothelial cells, which trigger the release of proinflammatory 
8Sha and Markovic-Plese Activated IL-1RI Signaling Induces Th17 Differentiation in RR MS
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 543
cytokines and chemokines that enhance neutrophil and mono-
cyte recruitment and further T cell recruitment to the CNS (39). 
Its complex regulation by multiple naturally occurring inhibitors, 
including recombinant IL-R antagonist opens new possibilities 
in the treatment of autoimmune diseases and particularly of MS 
(40, 41). New strategies for the selective targeting of only some of 
the effector mechanisms of the IL-1RI signaling pathway using 
selective reversible non-competitive small peptide antagonist of 
IL-1RI hold promise as safe and effective treatments for autoim-
mune diseases (42).
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